Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 31, 2014 (12 years ago)

Virazole (Ribavirin for Inhalation Solution, USP)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Non-Sterility: Valeant's laboratory observed a positive microbial contamination of Virazole lot 340353F, during testing at the 12 month stability pull.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Virazole (Ribavirin for Inhalation Solution, USP), Sterile Lyophilized For Administration by Aerosol Inhalation Only, Rx only, Contents: Four 6 g vials, 100 mL, Distributed by: Valeant Pharmaceuticals North America, Bridgewater, NJ 08807 USA, NDC 0187-0007-14.

Affected NDC 0187-0007-14

Compare with the code on your package — it is the most precise check available.

Drug: Ribavirin

Recalling firm
Valeant Pharmaceuticals North America LLC
NDC code
0187-0007-14
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0379-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ribavirin recalls

See all
Class II · Moderate risk

Ribavirin active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-879-2015
Class II · Moderate risk

Ribavirin

Labeling:Label Mixup; RIBAVIRIN, Capsule, 200 mg may be potentially mislabeled as MODAFINIL, Tablet, 50 mg (1/2 of 100 MG Tablet), NDC 55253080130, Pedigree: AD21787_4, EXP: 5/1/2014; DESIPRAMINE HCL, Tablet, 50 mg, NDC 45963034302, Pedigree: AD30140_7, EXP: 5/7/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-727-2014

Other recalls by Valeant Pharmaceuticals North America LLC

All 2014 recalls
Class III · Low risk

Diltiazem HCl CD capsules

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 68682-521-01 D-0491-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0798-30 D-0490-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0797-30 D-0489-2019
Class III · Low risk

Cardizem CD

Failed Dissolution Specifications: high out of specification results for dissolution when measuring the amount of drug released at certain time points.

Terminated Dissolution failure Valeant Pharmaceuticals North America LLC NDC 0187-0796-30 D-0488-2019